v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|||||
| Operating Expenses: | ||||||||
| Research and development | $ 583,177 | $ 316,473 | $ 1,688,474 | $ 689,217 | ||||
| Research and development - related parties | 53,347 | 298,879 | 158,401 | 1,287,583 | ||||
| General and administrative | 3,418,628 | 3,519,605 | 10,405,933 | 8,740,067 | ||||
| General and administrative - related parties | 82,519 | 5,261 | 462,081 | |||||
| Total Operating Expenses | 4,055,152 | 4,217,476 | 12,258,069 | 11,178,948 | ||||
| Loss From Operations | (4,055,152) | (4,217,476) | (12,258,069) | (11,178,948) | ||||
| Other (Expense) Income: | ||||||||
| Gain on settlement of liabilities | 472,677 | 927,698 | ||||||
| Other income | 12,308 | 12,308 | ||||||
| Interest expense | (7,348) | (5,455) | (22,117) | (130,634) | ||||
| Interest (expense) income – related parties | (1,536) | (14,201) | 1,495 | (42,279) | ||||
| Loss on extinguishment of convertible notes payable, net | (9,737) | |||||||
| Loss on impairment of goodwill | (18,872,850) | (18,872,850) | ||||||
| Change in fair value of derivative liabilities | 1,449,908 | 22,043,391 | 14,167,560 | (10,342,337) | ||||
| Change in fair value of accrued issuable equity | (9,405) | |||||||
| Offering costs allocated to warrant liabilities | (604,118) | |||||||
| Total Other (Expense) Income, Net | (17,431,826) | 22,508,720 | (4,725,912) | (10,198,504) | ||||
| (Loss) Income Before Income Taxes | (21,486,978) | 18,291,244 | (16,983,981) | (21,377,452) | ||||
| Income tax benefit | 5,612 | 16,587 | ||||||
| Net (Loss) Income | (21,486,978) | 18,296,856 | (16,983,981) | (21,360,865) | ||||
| Other Comprehensive (Loss) Income: | ||||||||
| Foreign currency translation adjustments | (1,871,072) | (530,817) | (4,507,204) | 65,018 | ||||
| Total Comprehensive (Loss) Income | $ (23,358,050) | $ 17,766,039 | $ (21,491,185) | $ (21,295,847) | ||||
| Basic and Diluted Net (Loss) Income per Common Share | ||||||||
| Basic (in Dollars per share) | $ (0.55) | $ 0.56 | $ (0.47) | $ (0.7) | ||||
| Diluted (in Dollars per share) | $ (0.55) | $ 0.23 | $ (0.47) | $ (0.7) | ||||
| Weighted Average Number of Common Shares Outstanding: | ||||||||
| Basic (in Shares) | 39,181,736 | [1] | 32,727,965 | 35,803,504 | [1] | 30,491,082 | ||
| Diluted (in Shares) | 39,181,736 | 33,709,584 | 35,803,504 | 30,491,082 | ||||
| ||||||||
| X | ||||||||||
- Definition Change in fair value of accrued issuable equity. No definition available.
|
| X | ||||||||||
- Definition Offering costs allocated to warrant liabilities. No definition available.
|
| X | ||||||||||
- Definition Amount of research and development (R&D) is a term to describe the effort a company devotes to the innovation, and improvement of its products and processes. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of nonoperating interest income (expense). No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of selling, general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|